

# Christoph Welsch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3268625/publications.pdf>

Version: 2024-02-01

97  
papers

2,798  
citations

218381

26  
h-index

189595

50  
g-index

100  
all docs

100  
docs citations

100  
times ranked

3743  
citing authors

#	ARTICLE	IF	CITATIONS
1	Upregulation of the Long Noncoding RNA HULC by Hepatitis C Virus and Its Regulation of Viral Replication. <i>Journal of Infectious Diseases</i> , 2022, 226, 407-419.	1.9	7
2	Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). <i>Lancet Regional Health - Europe</i> , The, 2022, 12, 100240.	3.0	50
3	Regulatory Role of Phospholipids in Hepatitis C Virus Replication and Protein Function. <i>Pathogens</i> , 2022, 11, 102.	1.2	1
4	SPCS1-Dependent E2-p7 processing determines HCV Assembly efficiency. <i>PLoS Pathogens</i> , 2022, 18, e1010310.	2.1	2
5	Diagnostic and prognostic significance of cell death markers in patients with cirrhosis and acute decompensation. <i>PLoS ONE</i> , 2022, 17, e0263989.	1.1	4
6	Distinct clinical phenotypes in a family with a novel truncating MEN1 frameshift mutation. <i>BMC Endocrine Disorders</i> , 2022, 22, 64.	0.9	0
7	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. <i>Gut</i> , 2021, 70, gutjnl-2019-320170.	6.1	47
8	Chronic liver disease negatively affects outcome in hospitalised patients with community-acquired pneumonia. <i>Gut</i> , 2021, 70, 221-222.	6.1	7
9	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	1.8	149
10	Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability. <i>Journal of Biological Chemistry</i> , 2021, 297, 101031.	1.6	2
11	Capnography monitoring of non-anesthesiologist provided sedation during percutaneous endoscopic gastrostomy placement: A prospective, controlled, randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 401-407.	1.4	13
12	Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors. <i>Journal of Biological Chemistry</i> , 2020, 295, 13862-13874.	1.6	10
13	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	1.8	282
14	Application of Contrast-Enhanced Ultrasound to Detect Hepatic Hydrothorax in Patients with Liver Cirrhosis. <i>Ultraschall in Der Medizin</i> , 2020, , .	0.8	4
15	Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?. <i>Journal of Hepatology</i> , 2020, 73, 980-982.	1.8	8
16	Anemia and Systemic Inflammation Rather than Arterial Circulatory Dysfunction Predict Decompensation of Liver Cirrhosis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1263.	1.0	11
17	Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , 2020, 27, 974-986.	1.0	12
18	Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure. <i>Liver International</i> , 2020, 40, 1457-1466.	1.9	46

#	ARTICLE	IF	CITATIONS
19	The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease. <i>Frontiers in Immunology</i> , 2020, 11, 1352.	2.2	13
20	Dysregulated Adaptive Immunity Is an Early Event in Liver Cirrhosis Preceding Acute-on-Chronic Liver Failure. <i>Frontiers in Immunology</i> , 2020, 11, 534731.	2.2	26
21	Translation of IRF-1 Restricts Hepatic Interleukin-7 Production to Types I and II Interferons: Implications for Hepatic Immunity. <i>Frontiers in Immunology</i> , 2020, 11, 581352.	2.2	2
22	THU-049-Impaired adaptive immunity is an early event in liver cirrhosis preceding acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2019, 70, e181-e182.	1.8	0
23	IL-22 and IL-22-Binding Protein Are Associated With Development of and Mortality From Acute-on-Chronic Liver Failure. <i>Hepatology Communications</i> , 2019, 3, 392-405.	2.0	33
24	Omega-3 and -6 fatty acid plasma levels are not associated with liver cirrhosis-associated systemic inflammation. <i>PLoS ONE</i> , 2019, 14, e0211537.	1.1	9
25	Near-Neighbor Interactions in the NS3-4A Protease of HCV Impact Replicative Fitness of Drug-Resistant Viral Variants. <i>Journal of Molecular Biology</i> , 2019, 431, 2354-2368.	2.0	3
26	Palmitoylation of Hepatitis C Virus NS2 Regulates Its Subcellular Localization and NS2-NS3 Autocleavage. <i>Journal of Virology</i> , 2019, 94, .	1.5	13
27	Unexpected Replication Boost by Simeprevir for Simeprevir-Resistant Variants in Genotype 1a Hepatitis C Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	3
28	Bacterial infection-triggered acute-on-chronic liver failure is associated with increased mortality. <i>Liver International</i> , 2018, 38, 645-653.	1.9	85
29	Vitamin D deficiency is associated with hepatic decompensation and inflammation in patients with liver cirrhosis: A prospective cohort study. <i>PLoS ONE</i> , 2018, 13, e0207162.	1.1	37
30	Glycogen Synthase Kinase 3 <sup>β</sup> Enhances Hepatitis C Virus Replication by Supporting miR-122. <i>Frontiers in Microbiology</i> , 2018, 9, 2949.	1.5	13
31	Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids. <i>Frontiers in Immunology</i> , 2018, 9, 723.	2.2	56
32	HCV NS5A dimer interface residues regulate HCV replication by controlling its self-interaction, hyperphosphorylation, subcellular localization and interaction with cyclophilin A. <i>PLoS Pathogens</i> , 2018, 14, e1007177.	2.1	27
33	Differential modulation of hepatitis C virus replication and innate immune pathways by synthetic calcitriol-analogs. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 183, 142-151.	1.2	12
34	Identification of glycogen synthase kinase 3 beta as a novel host factor of hepatitis C virus replication. <i>Journal of Hepatology</i> , 2017, 66, S321-S322.	1.8	0
35	High sustained virologic response rates in hepatitis C virus genotype 3 patients with and without cirrhosis treated with daclatasvir/sofosbuvir or velpatasvir/sofosbuvir ± ribavirin according to baseline resistance analysis. <i>Journal of Hepatology</i> , 2017, 66, S83.	1.8	3
36	Protease Inhibitor Resistance. , 2017, , 21-40.		0

#	ARTICLE	IF	CITATIONS
37	Molecular mechanisms of fitness compensation in drug resistance-associated NS3 protease variants in hepatitis C. <i>Journal of Hepatology</i> , 2017, 66, S319.	1.8	0
38	Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response. <i>PLoS ONE</i> , 2017, 12, e0171755.	1.1	49
39	The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 856-865.	1.9	75
40	Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix 1±18. <i>Scientific Reports</i> , 2016, 6, 19526.	1.6	14
41	Differential Kinetics of Coagulation Factors and Natural Anticoagulants in Patients with Liver Cirrhosis: Potential Clinical Implications. <i>PLoS ONE</i> , 2016, 11, e0155337.	1.1	11
42	Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN- $\beta$ induction by efficient MAVS cleavage. <i>Journal of Hepatology</i> , 2015, 62, 779-784.	1.8	12
43	Protease Inhibitor Resistance. , 2015, , 1-17.		0
44	Evolution of a Cell Culture-Derived Genotype 1a Hepatitis C Virus (H77S.2) during Persistent Infection with Chronic Hepatitis in a Chimpanzee. <i>Journal of Virology</i> , 2014, 88, 3678-3694.	1.5	27
45	Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation. <i>Nature Medicine</i> , 2014, 20, 927-935.	15.2	130
46	Genetic barrier and variant fitness in hepatitis C as critical parameters for drug resistance development. <i>Drug Discovery Today: Technologies</i> , 2014, 11, 19-25.	4.0	11
47	P1309 HCV MUTANTS RESISTANT TO MACROCYCLIC NS3-4A PROTEASE INHIBITORS SUPPRESS INTERFERON- $\beta$ INDUCTION BY EFFICIENT MAVS CLEAVAGE. <i>Journal of Hepatology</i> , 2014, 60, S531.	1.8	0
48	Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in patients naive to direct antivirals. <i>Antiviral Therapy</i> , 2014, 19, 455-461.	0.6	4
49	Class A Scavenger Receptor 1 (MSR1) Restricts Hepatitis C Virus Replication by Mediating Toll-like Receptor 3 Recognition of Viral RNAs Produced in Neighboring Cells. <i>PLoS Pathogens</i> , 2013, 9, e1003345.	2.1	73
50	Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 803-811.	0.6	1
51	Base Pairing between Hepatitis C Virus RNA and MicroRNA 122 3' of Its Seed Sequence Is Essential for Genome Stabilization and Production of Infectious Virus. <i>Journal of Virology</i> , 2012, 86, 7372-7383.	1.5	74
52	Ketoamide Resistance and Hepatitis C Virus Fitness in Val55 Variants of the NS3 Serine Protease. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1907-1915.	1.4	32
53	Clinical relevance of HCV antiviral drug resistance. <i>Current Opinion in Virology</i> , 2012, 2, 651-655.	2.6	21
54	1214 MECHANISMS FOR KETOAMIDE ESCAPE IN VAL55 VARIANTS OF THE HCV NS3/4A PROTEASE DOMAIN. <i>Journal of Hepatology</i> , 2012, 56, S482.	1.8	0

#	ARTICLE	IF	CITATIONS
55	New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. <i>Gut</i> , 2012, 61, i36-i46.	6.1	168
56	Modulation of replication efficacy of the hepatitis C virus replicon Con1 by site-directed mutagenesis of an NS4B aminoterminal basic leucine zipper. <i>Journal of Viral Hepatitis</i> , 2012, 19, 775-783.	1.0	3
57	Peptidomimetic Escape Mechanisms Arise via Genetic Diversity in the Ligand-Binding Site of the Hepatitis C Virus NS3/4A Serine Protease. <i>Gastroenterology</i> , 2012, 142, 654-663.	0.6	17
58	Will Interferon-Free Regimens Prevail?. <i>Gastroenterology</i> , 2012, 142, 1351-1355.	0.6	15
59	1240 ANALYSIS OF COMPLEX MUTATION PATTERNS IN THE HCV QUASISPECIES OF PATIENTS TREATED WITH TELAPREVIR OR BOCEPREVIR. <i>Journal of Hepatology</i> , 2011, 54, S490.	1.8	1
60	1348 VIRAL HETEROGENEITY IN HCV NS5A GENOME IS LOW IN PATIENTS WITH FAVORABLE IL28B GENOTYPES. <i>Journal of Hepatology</i> , 2011, 54, S532.	1.8	0
61	Protease Inhibitor-Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious Virus. <i>Gastroenterology</i> , 2011, 140, 667-675.	0.6	129
62	Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. <i>Journal of Hepatology</i> , 2011, 55, 554-563.	1.8	47
63	Impact of Ribavirin on HCV Replicon RNA Decline during Treatment with Interferon- $\alpha$ and the Protease Inhibitors Boceprevir or Telaprevir. <i>Antiviral Therapy</i> , 2011, 16, 695-704.	0.6	11
64	Comparison of Envelope 2 CD81 binding regions in PBMC-derived versus serum-derived hepatitis C virus isolates: higher conservation of CD81 region 2 in PBMC isolates. <i>Journal of Viral Hepatitis</i> , 2011, 18, 181-192.	1.0	2
65	Regulation of the Production of Infectious Genotype 1a Hepatitis C Virus by NS5A Domain III. <i>Journal of Virology</i> , 2011, 85, 6645-6656.	1.5	40
66	Contribution of charged and polar residues for the formation of the E1-E2 heterodimer from Hepatitis C Virus. <i>Journal of Molecular Modeling</i> , 2010, 16, 1625-1637.	0.8	10
67	Dimerization of the hepatitis C virus nonstructural protein 4B depends on the integrity of an aminoterminal basic leucine zipper. <i>Protein Science</i> , 2010, 19, 1327-1336.	3.1	11
68	Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome. <i>Journal of Viral Hepatitis</i> , 2010, 17, 217-221.	1.0	0
69	754 IMPACT OF RIBAVIRIN ON SUBGENOMIC HEPATITIS C VIRUS RNA DECAY DURING TREATMENT WITH INTERFERON ALFA AND THE PROTEASE INHIBITOR TELAPREVIR. <i>Journal of Hepatology</i> , 2010, 52, S293-S294.	1.8	1
70	776 GENETIC DIVERSITY IN THE LIGAND-BINDING SITE OF THE NS3.4A PROTEASE AND IMPACT ON PEPTIDOMIMETIC INHIBITORS IN HCV-1A. <i>Journal of Hepatology</i> , 2010, 52, S301-S302.	1.8	0
71	Primary Actinomycosis of the Liver Mimicking Malignancy. <i>Zeitschrift Fur Gastroenterologie</i> , 2009, 47, 1062-1064.	0.2	7
72	Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. <i>Hepatology</i> , 2009, 50, 1709-1718.	3.6	282

#	ARTICLE	IF	CITATIONS
73	Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX) Tj ETQq1 1 0.784314 rgBT /Over Biomedical and Life Sciences, 2009, 877, 4001-4006.	1.2	23
74	Clinical relevance of the 2'5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C. Journal of Hepatology, 2009, 50, 49-58.	1.8	10
75	RNA-Binding Activity of Hepatitis C Virus NS4B: A Novel Target for Small Molecule Inhibitors. Gastroenterology, 2009, 137, 2170-2172.	0.6	12
76	348 HOMODIMERIZATION OF THE HEPATITIS C VIRUS NON-STRUCTURAL 4B PROTEIN REQUIRES AN INTACT BASIC LEUCINE ZIPPER. Journal of Hepatology, 2009, 50, S133-S134.	1.8	0
77	616 EFFECT OF RIBAVIRIN ON THE FREQUENCY OF RNASE L CLEAVAGE SITES WITHIN THE HEPATITIS C VIRAL GENOME. Journal of Hepatology, 2009, 50, S226-S227.	1.8	1
78	971 MOLECULAR MECHANISMS OF CROSS-RESISTANCE IN PEPTIDOMIMETIC PROTEASE INHIBITORS FOR STAT-C. Journal of Hepatology, 2009, 50, S352.	1.8	0
79	Evaluation of the MLH1 I219V alteration in DNA mismatch repair activity and ulcerative colitis. Inflammatory Bowel Diseases, 2008, 14, 605-611.	0.9	13
80	Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biology, 2008, 9, R16.	13.9	74
81	Novel Hepatitis C Drugs in Current Trials. Clinics in Liver Disease, 2008, 12, 529-555.	1.0	20
82	Validity of N-terminal propeptide of the brain natriuretic peptide in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease. European Journal of Gastroenterology and Hepatology, 2008, 20, 865-873.	0.8	19
83	Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation. Journal of Clinical Virology, 2007, 38, 146-148.	1.6	16
84	[66] MOLECULAR BASIS FOR VX-950 RESISTANCE. Journal of Hepatology, 2007, 46, S30.	1.8	0
85	[654] PREDICTION OF VIROLOGIC RESPONSE IN HCV GENOTYPE 1A-INFECTED PATIENTS ACCORDING TO AMINO ACID PATTERN IN NS5A USING STATISTICAL LEARNING ALGORITHMS FOR CLASSIFICATION. Journal of Hepatology, 2007, 46, S247-S248.	1.8	1
86	Identification and in silico characterization of a novel compound heterozygosity associated with hereditary aceruloplasminemia. Scandinavian Journal of Gastroenterology, 2007, 42, 1088-1094.	0.6	13
87	Structural and functional comparison of the non-structural protein 4B in flaviviridae. Journal of Molecular Graphics and Modelling, 2007, 26, 546-557.	1.3	29
88	Correlation of amino acid variations within nonstructural 4B protein with initial viral kinetics during interferon-alpha-based therapy in HCV-1b-infected patients. Journal of Viral Hepatitis, 2007, 14, 338-349.	1.0	14
89	Somatic hypermutation and mRNA expression levels of the BCL-6 gene in patients with hepatitis C virus-associated lymphoproliferative diseases. Journal of Viral Hepatitis, 2007, 14, 484-491.	1.0	14
90	Mutations in the MutS1 interaction interface of MLH1 can abolish DNA mismatch repair. Nucleic Acids Research, 2006, 34, 6574-6586.	6.5	61

#	ARTICLE	IF	CITATIONS
91	Amino Acid Variations in Hepatitis C Virus P7 and Sensitivity to Antiviral Combination Therapy with Amantadine in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2006, 11, 507-519.	0.6	35
92	Structural and functional analysis of a novel mutation of CYP21B in a heterozygote carrier of 21-hydroxylase deficiency. <i>Human Genetics</i> , 2005, 117, 558-564.	1.8	15
93	Clinical Significance of In Vitro Replication-Enhancing Mutations of the Hepatitis C Virus (HCV) Replicon in Patients with Chronic HCV Infection. <i>Journal of Infectious Diseases</i> , 2005, 192, 1710-1719.	1.9	21
94	Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression. <i>Journal of Viral Hepatitis</i> , 2004, 11, 310-318.	1.0	15
95	398 HCV-associated mixed cryoglobulinemia: Importance of mutations within the HCV E2 region and CD81 expression on peripheral B lymphocytes. <i>Journal of Hepatology</i> , 2004, 40, 118-119.	1.8	0
96	Association of HCV-related mixed cryoglobulinemia with specific mutational pattern of the HCV E2 protein and CD81 expression on peripheral B lymphocytes. <i>Blood</i> , 2004, 104, 1228-1229.	0.6	17
97	Pharmacokinetics of Peginterferons. <i>Seminars in Liver Disease</i> , 2003, 23, 023-028.	1.8	106